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Parvin-b is an adaptor protein that binds to integrin-linked kinase (ILK) and is signiﬁcantly down-
regulated in breast tumors and breast cancer cell lines. We treated the breast cancer cell line MCF7 with
24-methylenecycloartanyl ferulate (24-MCF), a g-oryzanol compound. We observed upregulation of
parvin-b (GenBank Accession No. AF237769) and peroxisome proliferator-activated receptor (PPAR)-g2
(GenBank Accession No. NM_015869). Among g-oryzanol compounds, only treatment with 24-MCF led
to the formation of reverse transcription-PCR products of parvin-b (650 and 500 bp) and PPAR-g2
(580 bp) in MCF7 cells, but not in T47D, SK-BR-3, or MDA-MB-231 cells. 24-MCF treatment increased the
mRNA and protein levels of parvin-b in MCF7 cells in a dose-dependent manner. We hypothesized that
there is a correlation between parvin-b expression and induction of PPAR-g2. This hypothesis was
investigated by using a promoter-reporter assay, chromatin immunoprecipitation, and an electrophoretic
mobility shift assay. 24-MCF treatment induced binding of PPAR-g2 to a peroxisome proliferator
response element-like cis-element (ACTAGGACAAAGGACA) in the parvin-b promoter in MCF7 cells in a
dose-dependent manner. 24-MCF treatment signiﬁcantly decreased anchorage-independent growth and
inhibited cell movement in comparison to control treatment with dimethyl sulfoxide. 24-MCF treatment
reduced the levels of GTP-bound Rac1 and Cdc42. Evaluation of Akt1 inhibition by 24-MCF revealed that
the half maximal effective concentration was 33.3 mM. Docking evaluations revealed that 24-MCF binds
to the ATP-binding site of Akt1(PDB ID: 3OCB) and the compound binding energy is -8.870 kcal/mol.
Taken together, our results indicate that 24-MCF treatment increases parvin-b expression, which may
inhibit ILK downstream signaling.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).l ferulate; CAF, cycloartenyl
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Integrin-linked kinase (ILK) overexpression is a hallmark of
several solid tumors [1e3]. Recent experiments suggest that
deregulation of ILK signaling can affect anchorage-independent cell
growth, cell survival, and oncogenic transformation [4,5]. Com-
plexes such as that of the adaptor protein PINCH (Particularly
Interesting Cys-His-rich protein) and parvin-b are important reg-
ulators of integrin-mediated signaling in breast cancer [1]. Parvin-be under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and is widely expressed in human/mammalian tissues [6]. It was
reported in recent studies that parvin-b expression is signiﬁcantly
downregulated in a number of breast cancer tumors [2], which
correlates with the upregulation of ILK signaling [1], suggesting
that parvin-b can suppress oncogenic ILK signaling [1]. However,
the biochemical functions of parvin-b remain unclear.
In recent years, speciﬁc dietary compounds (dietary lipids, iso-
ﬂavones, and other ﬂavonoids) have been the focus of scientiﬁc
interest because they transactivate peroxisome proliferator-
activated receptors (PPARs) [7]. PPARs mainly function as hetero-
dimers in associationwith the co-activator complex, which binds to
peroxisome proliferator response elements (PPREs) [8], with a DNA
recognition motif composed of a direct repeat separated by one
nucleotide with a consensus sequence of RGGTGA-A-AGGTCA [9].
PPREs are present in the promoters of target genes and underlie the
transactivation and transrepression of various genes [8].
24-methylenecycloartanyl ferulate (24-MCF), a gamma-
oryzanol (g-oryzanol) compound, is a non-toxic dietary com-
pound that reduces the risks of cancer, hyperlipidemia, and plasma
cholesterol [10]. However, its precise molecular mechanism has not
been fully elucidated.
Using a cDNA microarray we found that parvin-b and PPAR-g2
expression were increased by 24-MCF treatment in the breast
cancer cell line MCF7 (data not shown). In the present study, we
aimed to investigatewhether a PPRE-like cis-element in the parvin-
b promoter was involved in the upregulation of parvin-b and
whether this upregulation can inhibit ILK downstream signaling.
2. Materials and methods
2.1. Materials
The rice bran compounds ferulic acid (FA), cycloartenyl ferulate
(CAF), 24-methylenecycloartanyl ferulate (24-MCF), and campes-
teryl ferulate (CSF) were provided by the National Academy of
Agricultural Science (Korea). Total RNA was extracted from breast
cancer cell lines using TRI-RNA reagent (Favorgen, Taiwan)
following the manufacturer's instructions. The human parvin-b
promoter was ampliﬁed by PCR fromMCF7 cell genomic DNA using
Taq DNA polymerase (Bionner, Korea), with the forward primer 50-
CTCGAGAGACCAAAAATAAGGCACGTTCAT-30, and the reverse
primer 50-AAGCTTGAGAAGTGAACCAGCCAGAGAAGC-30. The
1.05 kb fragment with XhoI and HindIII site was ligated into the
equivalent site of pGL3-basic, a promoter-less ﬁreﬂy luciferase re-
porter vector. Full-length human PPAR-g1 (Accession No.
NM_138712) and PPAR-g2 (Accession No. NM_015869) were
subcloned into the p3XFLAG-CMV 7.1 vector. Antibodies were
purchased as indicated: vs parvin-b (Santa Cruz Biotechnology,
Santa Cruz, CA); Rac1 and Cdc42 (Abcam, Cambridge, MA) and Flag
M2 and Anti-Flag M2 afﬁnity gel (Sigma, St. Louis, Mo).
2.2. Cell culture and cell viability
The human breast cancer cells MCF7, MDA-MB-231, T47D, SK-
BR-3, and the non-cancerous human breast cell line MCF-10A,
were cultured in Dulbecco's Modiﬁed Eagle's Medium (DMEM,
HyClone, Logan, UT) supplemented with 10% heat-inactivated fetal
bovine serum (FBS, HyClone, UT), 100 U/ml penicillin, and 100 mg/
ml streptomycin in 5% CO2 at 37 C. Cell viability was determined
using an MTT kit (Sigma, St. Louis, Mo) according to the manufac-
turer's instructions. Brieﬂy, 1 104 cells were seeded in triplicate in
96-well plates. MCF7, MDA-MB-231, SK-BR-3, and MCF-10A cells
were treated with 24-MCF in a dose-dependent manner and
incubated for 24 h. Cell viability was measured at 490 nm using axMark Microplate Absorbance Spectrometer (Bio-Rad, Philadel-
phia, PA). All experiments were performed in triplicate.2.3. Reverse transcription (RT)-PCR
Total RNA was isolated using the TRI-RNA reagent (Favorgen,
Taiwan) according to the manufacturer's instructions. Thereafter,
1 mg of total RNA was converted to cDNA using an oligo-dT primer
and AccurPower RT premix (Bioneer, Korea) in a 20 ml reaction. The
PCR products were generated using AccurPower PCR Mix (Bioneer,
Korea) and the following primers: parvin-b, 50-TGTGAAGCAGCTG-
GAGGAAG-30 and 50-AAGTGCAT GGCCAGAGAGAC-30; PPAR-g1, 50-
TCTCTCCGTAATGGAAGACC-30 and 50-GCATTAT GAGACATCCCCAC-
30; PPAR-g2, 50-GCGATTCCTTCACTGATAC-30 and 50-GCATTAT
GAGACATCCCCAC-30. The ampliﬁed PCR products were separated
on a 2.0% agarose gel and visualized using ethidium bromide
(Sigma, St. Louis, Mo).2.4. Western blot analysis
Cells at 70e80% conﬂuency were treated with 24-MCF for 24 h.
Cells were washed twice with ice-cold phosphate-buffered saline
(PBS) and lysed on ice for 30 min in RIPA buffer (Cell Signaling,
Danvers, MA) containing 1  protease inhibitor cocktail reagent
(ThermoFisher, Waltham, MA) and 1  phosphatase inhibitor
(Sigma, St. Louis, Mo). The extract was centrifuged at 14,000 rpm
for 15 min at 4 C to remove cellular debris. Thereafter, 20 mg of
protein was separated on a 4e12% NuPAGE gel (Invitrogen, San
Diego, CA), transferred to a nitrocellulose membrane using stan-
dard procedures (Invitrogen, San Diego, CA), and probed by West-
ern blot with the indicated antibodies.2.5. Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was modiﬁed from a previously described
strategy [11]. Chromatin was prepared from MCF7 cells that had
been transiently transfected with 3XFLAG-vector, 3XFLAG-PPAR-g1
and 3XFLAG-PPAR-g2 using the Lipofectamine LTX Plus Reagent
(Invitrogen, San Diego, CA). Immunoprecipitated samples were
prepared for PCR and analyzed using the following primers tar-
geting the parvin-b promoter: forward, 50-GAGAGCTCAGA-
GAGCAAAGA-30 and reverse, 50-GAGAGCACCGCAGATTCACG-30. PCR
was performed with 35 cycles (denaturation for 30 s at 94 C,
annealing for 30 s at 70 C, and extension for 90 s at 72 C) and a
ﬁnal extension at 72 C for 7 min. PCR products were detected on a
2% agarose gel.2.6. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared fromMCF7 cells using a NE-PER
Nuclear and Cytoplasmic Extraction Reagents kit (ThermoFisher,
Waltham,MA) according to themanufacturer's instructions. For the
EMSA, 5 mg of nuclear extracts by 24-MCF treatment and biotin
end-labeled PPRE-like cis-element (50-ACTAGGACAAAGGACA-30)
probes were directly added to binding buffer (0.01 M phosphate
buffer, pH 7.5, 0.15 M NaCl, and 2.7 mM KCl). The mixture was
incubated on ice for 30 min and at room temperature for 30 min.
For the competition assay, a 100-fold excess of unlabeled PPRE-like
cis-element was used along with biotin end-labeled PPRE-like
sequence probes. The DNA-protein complexes were resolved on 5%
non-denaturing polyacrylamide gels in 0.5  TBE buffer and
detected using a chemiluminescence reagent (ThermoFisher, Wal-
tham, MA) according to the manufacturer's instructions.
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Wound migration assays were conducted using MCF7 cells
treated with 24-MCF. A scratch wound was made using a pipette
tip. DMEM was replaced and wounds were photographed at 0 and
24 h. The Rac1 and Cdc42 assay was modiﬁed from a previously
described strategy [12]. Lysates were centrifuged at 14,000 rpm for
15min. Glutathione S-transferase (GST)-PAK fusion proteins on GST
beads (GE Healthcare, Pittsburgh, PA) were added to the superna-
tant in order to pulldown active Rac1 and Cdc42 proteins, followed
by incubation at 4 C for 30 min. The beads were washed three
times with 1 ml of the buffer used to lyse cells. Rac1 and Cdc42
proteins were eluted with sample buffer and run on a 4e12%
NuPAGE gel (Invitrogen, San Diego, CA). Blots were probed with
anti-Rac1 and anti-Cdc42 antibodies to quantify the levels of the
activated GTPases. Protein bands were visualized with an enhanced
chemiluminescence reagent (Amersham Pharmacia Biotech, Pis-
cataway, NJ).
2.8. Anchorage-independent growth assay
MCF7 cells treated with 24-MCF were harvested, pipetted to
generate a single-cell suspension in DMEM (HyClone, Logan, UT)
supplemented with 10% FBS at a density of 1  104 cells/ml, and
layered over 7 ml of 0.35% DMEM agar containing 10% FBS in a 35-
mm tissue culture dish. The cells were cultured at 37 C in 5% CO2
for 21 days and stained with 0.04% crystal violet (Sigma, St. Louis,
Mo) and 2% ethanol prepared in PBS. Colonies containingmore than
eight cells were counted under a microscope.
2.9. In vitro AKT1 kinase assay
To test the speciﬁcity as an Akt1 inhibitor, SelectScreen proﬁling
Service (Invitrogen, San Diego, CA) was used with FRET-based Z0-
LYTE kit. The reactionwas performedwith a serial 3-fold dilution of
24-MCF and 10 mMATP and Akt1 kinase substrates according to the
manufacturer's instructions.
2.10. Docking study
Docking of 24-MCFwas assessed using AutoDock vina and the 3-
dimensional X-ray structure of human Akt1 kinase (PDB ID: 3OCB).
A docking grid box was generated for grid calculations with di-
mensions of x: 74  y: 80  z: 60 Å and center coordinates of x:
12.246  y: 1.333  z: 22.469. Docking simulation was performed
ten times with tenmodels (representing ten conformations) and an
energy range of 4. The best docking position for 24-MCF was pre-
dicted to be the ATP-binding site of Akt1.
2.11. Statistical analyses
All data was evaluated by One-way Analysis of Variance
(ANOVA). A value of p < 0.05 was considered to be statistically
signiﬁcant.
3. Results
3.1. 24-MCF treatment increases parvin-b and PPAR-g2 gene
expression in MCF7 cells
In the current study, the mRNA levels of parvin-b and PPAR-g2
were higher in MCF7 cells treated with 100 mM 24-MCF than in
those treated with FA, CAF, and CSF (Fig. 1A). The increase in the
mRNA level of parvin-b appeared to correlate with regulation of
PPAR-g2 inMCF7 cells. In addition, 24-MCF treatment increased themRNA and protein levels of parvin-b in MCF7 cells in a dose-
dependent manner over the range of concentrations tested (25,
50, and 100 mM) (Fig. 1B). We tested whether PPAR-g2 induced
parvin-b expression by co-transfecting MCF7 cells with different
ratios of the 3XFLAG-PPAR-g1 and 3XFLAG-PPAR-g2 plasmids.
Parvin-b mRNA expression was signiﬁcantly increased when the
ratio of the PPAR-g2-encoding plasmid to the PPAR-g1-encoding
plasmid was high, but not when the ratio of the PPAR-g1-
encoding plasmid to the PPAR-g2-encoding plasmid was high
(Fig. 1C). We performed a MTT assay to examine the possibility that
the increase in parvin-b and PPAR-g2 expression was due to the
stimulation of cell viability. Treatment with various concentrations
of 24-MCF for 24 h did not affect the viability of the breast cancer
cells MDA-MB-231, SK-BR-3, MCF7 or the non-cancerous breast
cells MCF-10A (Fig. 1D).
3.2. PPAR-g2 interacts with parvin-b through a PPRE-like cis-
element according to the EMSA and ChIP
To evaluate whether PPAR-g2 induces parvin-b expression, we
examined the promoter of the parvin-b gene. This promoter con-
tains PPRE-like cis-elements, which regulate its expression, in the
PPAR-g2-binding site located between 570 and 586 bp in the 50
ﬂanking sequence. First, we tested whether activation of the par-
vin-b promoter was regulated upon 24-MCF treatment. Activation
of the parvin-b promoter was signiﬁcantly increased by 24-MCF
treatment in a dose-dependent manner, demonstrating 24-MCF
responsiveness of the cloned parvin-b promoter fragment (Fig. 2A).
Second, we investigated whether PPAR-g2 can bind to the par-
vin-b promoter, which contains PPRE-like cis-elements, by per-
forming a modiﬁed ChIP-PCR assay [11]. This assay allowed
effective pulldown and elution of 3XFLAG-PPAR-g1 and PPAR-g2
from formaldehyde-ﬁxed DNA containing the PPRE-like cis-
element in the parvin-b promoter. Only 3XFLAG-PPAR-g2 enriched
the PPRE-like cis-element (50-ACTAGGAC AAAGGACA-30) in the
parvin-b promoter (Fig. 2B). No enrichment was observed with the
control or 3XFLAG-PPAR-g1 (Fig. 2B). These results indicate that
PPAR-g2 is associated with parvin-b expression in MCF7 cells.
Third, we examined whether parvin-b transactivation was
induced by PPAR-g2 expression dependent on 24-MCF treatment.
We investigated this by performing the EMSA using aMCF7 nuclear
extract, PPAR-g2-induced by 24-MCF treatment (Fig. 1A) and a
biotin-labeled parvin-b probe, which contained the PPRE-like cis-
element of the parvin-b promoter. 24-MCF treatment steadily
increased the amount of this DNA-protein complex in a dose-
dependent manner (Fig. 2C). However, there was competition be-
tween the complex and the non-biotin-labeled PPRE-like cis-
element probe (Fig. 2C), indicating 24-MCF responsiveness of the
conserved PPRE-like cis-element of the parvin-b promoter.
3.3. 24-MCF treatment inhibits MCF7 cell migration through Rac1
and Cdc42 signaling
Wound healing assays are models of in vitro cell movement
required to facilitate wound closure [13]. To explore inhibition of
MCF7 cell migration by 24-MCF treatment, we cultured MCF7 cells
in 12-well plates in complete DMEM and then DMEM containing 2%
FBS overnight. A scratch wound was created in the MCF7 cell
monolayer using a pipette tip, and cell movement was monitored
by microscopy. At 24 h, movement of cells was inhibited by treat-
ment with 25e100 mM 24-MCF, whereas the movement of cells
treated with DMSO was increased (Fig. 3A). Next, we determined
whether the effects of 24-MCF treatment are related to the GTPases
Rac1 and Cdc42. We used beads coated with GST-PBD (PAK1 p21-
binding domain) to pulldown active Rac1 and Cdc42 from the
Fig. 1. 24-MCF treatment increases the mRNA levels of parvin-b and PPAR-g2 in MCF7 cells. (A) MDA-MB-231, T47D, SK-BR-3, and MCF7 breast cancer cells were treated with g-
oryzanol compounds FA, CAF, 24-MCF, and CSF for 24 h. RT-PCR analyses of parvin-b, PPAR-g1, and PPAR-g2 expression were performed using gene-speciﬁc primers, as described in
Materials and methods. Cells treated with DMSO alone were used as controls. (B) RT-PCR and Western blot were performed on mRNA and protein of parvin-b expression in MCF7
cells treated with various concentrations of 24-MCF. (C) Overexpression of PPAR-g2 signiﬁcantly increased parvin-bmRNA expression. Protein expression was measured byWestern
blotting with anti-Flag antibody. (D) Effects of 24-MCF treatment on the viability of MDA-MB-231, MCF7, SK-BR-3, and MCF-10A cells. In total, 1  104 cells were treated with various
concentrations of 24-MCF at 37 C for 24 h. The percentage of viable cells was determined using the MTT assay. Data are means ± SE of triplicate against 24-MCF concentrations.
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levels of active GTP-bound Rac1 and Cdc42 in comparison to the
total levels of these proteins (Fig. 3B).Fig. 2. Identiﬁcation of a PPRE-like cis-element in the human parvin-b promoter. (A) Lucifer
cell lines were transiently co-transfected with a ﬁreﬂy luciferase reporter-driven Parvin-b pro
luciferase values are shown (n ¼ 3, p < 0.05). (B) ChiP assay of MCF7 cells used in the screen
gel, and elution was performed using Flag-peptide. Immunoblots fromMCF7 cell lysates dem
experiments performed with biotin-labeled PPRE-like cis-element (ACTAGGACAAAGGACA)
MCF treatment nuclear extracts; Lane 4, 100 mM of 24-MCF treatment nuclear extract plus3.4. 24-MCF treatment inhibits anchorage-independent growth of
MCF7 cells
ILK overexpression promotes anchorage-independent cell sur-
vival [13] and overexpression of parvin-b can inhibit colonyase reporter assays indicating 24-MCF responsiveness of the Parvin-b promoter. MCF7
moter or a Renilla luciferase reporter control vector. Normalized ﬁreﬂy luciferase/Renilla
described in Ref. [11]. Immunoprecipitation was performed using Anti-Flag M2 afﬁnity
onstrating expression of the 3XFLAG-PPAR-g1 and 3XFLAG-PPAR-g2 plasmid. (C) EMSA
in Parvin-b promoter. Lane 1, DMSO; Lane 2, 3, 50 mM and 100 mM, respectively, of 24-
100-fold excess non-labeled PPRE-like cis-element.
Fig. 3. 24-MCF treatment effect on MCF7 cell migration, activated Rac1 and Cdc42, and anchorage-independent growth. (A) 24-MCF treatment inhibition at the healing edge in
wound assay. Conﬂuent MCF7 monolayers were damaged by scratching a linear wound using yellow pipette tip and incubated in DMEM containing 2% FBS for 24 h. The red line
indicates where the scratch was made. (B) Effects of 24-MCF treatment on the activity of Rac1 and Cdc42 in MCF7 cells. The activation levels of Rac1 and Cdc42 were examined by
pulldown and Western blot analyses as described in Materials and Methods. Densitometric quantiﬁcation was performed on scanned immunoblot images using Multi Gauge
Version 3.1 (FujiFilm, Tokyo, Japan). (C) 24-MCF regulated anchorage-independent growth of MCF7 cells. Cells preincubated in 24-MCF-containing medium for 12 h and then MCF7
cells (1  104) were reseeded in 0.35% agar in DMEM supplemented 10% FBS using 35-mm culture dish and allowed to grow for 21 days in the presence of 24-MCF-free medium. Cell
colonies were stained with 0.04% crystal violet and counted. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)
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there is an inverse relationship between parvin-b expression and
ILK signaling [1], indicating that parvin-b inhibits ILK signaling.
Therefore, we investigated whether 24-MCF treatment inhibited
the anchorage-independent survival of MCF7 cells. 24-MCF treat-
ment signiﬁcantly attenuated the transformed phenotype of MCF7
cells, in comparison to cells treated with DMSO (Fig. 3C).
3.4.1. 24-MCF inhibits Akt1 kinase activity
We evaluated whether 24-MCF could inhibit Akt1 kinase ac-
tivity in a cell-free system, using Z0-LYTE™ Ser/Thr 6 peptide. Z0-
LYTE™ Ser/Thr 6 peptide phosphorylation can directly reﬂect Akt1
kinase activity.
As shown in Fig. 4A, 24-MCF inhibited Akt1 activity in a dose-
dependent manner (3-fold serial dilution). These effects were eval-
uated in the presence of 10 mM ATP. A dose-response curve was
plotted, and the EC50 of 24-MCF for Akt1 kinase inhibition was
calculated to be 33.3 mM. We also performed blind docking of 24-Fig. 4. 24-MCF inhibits Akt1 kinase activity. (A) Inhibition of Akt1 by 24-MCF measured b
centration of ATP was 10 mM. Phosphorylation of Z0-LYTE Ser/Thr 6 peptide was calculated ac
MCF concentrations. (B) (Left) Proposed binding model of 24-MCF/Akt1. Crystal structure of h
24-MCF formed hydrogen bond with Glu191. Several residues, including Val164, His194,
Deﬁnition of the grid box for the binding site (ATP pocket).MCF to the ATP target using Autodock vina by setting grid sizes
that included the entire ATP molecule. 24-MCF compound (Yellow
color) binds to the ATP-binding site of Akt1 (PDB ID: 3OCB) and the
repeat average of compound binding energy is 8.870 kcal/mol
(Fig.4B). The predicted bindingmodel showed that these interactions
are hydrophobic (Red) and hydrogen (Orange). The hydrogen-donor
forms an interactionwith Glu191, and hydrophobic interactions form
with Val164, His194, Phe161, and Asp292 in Akt1.
4. Discussion
In this study, we ﬁrst demonstrated that expression of parvin-b
and PPAR-g2, but not PPAR-g1, was signiﬁcantly increased in MCF7
cells treated with 24-MCF, but not in T47D, SK-BR-3, MDA-MB-
231 cells. The potential to regulate PPAR-g gene expression in vivo is
unknown. Comparison of cDNA encoding PPAR-g2 with that
encoding PPAR-g1 suggests that these two proteins differ only in
their NH2-terminal 30 amino acids [6]. These two isoforms arey a Z0-LYTE kinase kit, as described in Materials and Methods. The ﬁnal reaction con-
cording to the manufacturer's instructions. Data are means ± SE of triplicate against 24-
uman Akt1 kinase in a complex with a 24-MCF in the ATP-binding site (PDB ID: 3OCB).
Phe161, and Asp292 displayed strong hydrophobic interactions with 24-MCF. (Right)
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differential mRNA splicing [14]. Only PPAR-g2 mRNA expression
was increased in MCF7 cells treated with 24-MCF. However, this
correlation was not linked to cell viability. The MTT assay showed
that 24-MCF treatment did not affect the viability of the breast
cancer cells MDA-MB-231, SK-BR-3, or MCF7, or the non-cancerous
breast cells MCF-10A. Instead, 24-MCF treatment may turn on
parvin-b expression in MCF7 breast cancer cells.
Luciferase-driven parvin-b promoter activity was dramatically
increased by 24-MCF treatment in a dose-dependent manner.
Parvin-b mRNA expression was increased by transiently trans-
fecting MCF7 cells with the 3XFLAG-PPAR-g2 plasmid. EMSA ex-
periments revealed that PPAR-g2 can bind to a PPRE-like cis-
element in the parvin-b promoter. 24-MCF treatment increased the
amount of this speciﬁc DNA-protein complex in a dose-dependent
manner in MCF7 nuclear extracts. However, there was speciﬁc
competition between this complex and the non-biotin-labeled
PPRE-like cis-element. A ChIP assay revealed that PPAR-g2, but
not PPAR-g1, bound directly to the parvin-b promoter. Taken
together, these results suggest that the PPRE-like cis-element in the
parvin-b promoter is responsible for upregulation of parvin-b
through recruitment of PPAR-g2 upon 24-MCF treatment.
Next, we investigated whether the increase in parvin-b
expression upon 24-MCF treatment changes the phenotype of
MCF7 cells using an anchorage-independent growth assay. 24-
MCF-treated cells formed signiﬁcantly fewer colonies in soft agar
than DMSO-treated cells. These results are similar to previous re-
ports that the overexpression of parvin-b suppresses colony for-
mation of both MDA-MD-231 and MCF7 cell lines [2] but do not
affect the intrinsic proliferative capacity [2,12]. Cell migration is
regulated in a Rho family GTPase-dependent by growth factor and
integrin-mediated cell-extracellular (ECM) interactions [15]. To
explore negative regulation of cell migration upon 24-MCF treat-
ment, we determined the amounts of active Rac1 and Cdc42 by a
GST pulldown assay. Levels of the GTP-bound active forms of Rac1
and Cdc42 were lower in 24-MCF-treated cells than in DMSO-
treated cells, indicating that parvin-b expression upon 24-MCF
treatment inhibited ILK-mediated Rac1 and Cdc42 activation
[16e18].
The effects of 24-MCF are observed at high concentrations
(25e100 mM), which is far higher than one would accept for a
pharmacological lead compound, indicating that non-speciﬁc in-
teractions might occur. However, 24-MCF inhibited Akt1 kinase
activity in a cell-free system. The EC50 values of 24-MCF against
Akt1 kinase activity was 33.3 mM. Additionally, we performed blind
docking using AutoDock Vina and the 3-dimensional X-ray crystal
structure of human Akt1 protein (PDB ID: 3OCB). 24-MCF binds to
the ATP-binding site of Akt1, indicating that 24-MCF has a high
afﬁnity for Akt1 and binds within a region that is important for
Akt1 kinase activity.
In conclusion, our study demonstrates that the functional PPRE-
like cis-element identiﬁed in the human parvin-b promoter is
responsible for upregulation of parvin-b expression upon 24-MCF
treatment. 24-MCF, a new potential ATP-competitive Akt1 inhibi-
tor, binds to the ATP-binding site of the Akt1 kinase (PDB ID: 3OCB).Acknowledgments
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